SAN FRANCISCO–(BUSINESS WIRE)–Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories: Tempo-iBMEC(TM) Human iPSC-derived Brain Microvascular Endothelial Cells Tempo-iPeri(TM) Human iPSC-derived Pericytes Tempo-iBMEC(TM) and Tempo-iPeri(TM) are critical for establishing patient-relevant blood-brain-barrier